AD		

GRANT NUMBER: DAMD17-97-1-7296

TITLE: Cyclin C Regulation of the Stress Response and Drug Sensitivity in Breast Cancer

PRINCIPAL INVESTIGATOR:

Randy Strich, Ph.D.

CONTRACTING ORGANIZATION:

Institute for Cancer Research

7701 Burholme Avenue, Philadelphia, PA 19111

REPORT DATE:

August 1999

TYPE OF REPORT:

Annual

PREPARED FOR:

U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188				
				<u> </u>			
1.	AGENCY USE ONLY (Leave blank,	2. REPORT DATE August 1999	3. REPORT Annual	TYPE AND DATES COV 8/1/98-7/31/99			
4.	TITLE AND SUBTITLE	11agast 1999	Ailliuai	5. FUNDING NUMBE			
	Cyclin C Regulation of the Stress Response and Drug Sensitivity in Breast Cancer			DAMD17-97-			
6.	AUTHOR(S) Randy Strich, Ph.D.						
7.	. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)			 PERFORMING OF REPORT NUMBER 			
	Institute for Cancer Research			REPORT NOMBE	1		
	7701 Burholme Avenue						
	Philadelphia, Pennsylvania	19111 r strich@fccc	edu				
_	ODONIO DINO MONITO DINO 105	-		10. SPONSORING/MO	NITORING		
9.	SPONSORING/MONITORING AGE			AGENCY REPOR			
	U.S. Army Medical Research						
	Fort Detrick, Maryland 21'	702-5012					
11.	SUPPLEMENTARY NOTES			<u> </u>			
12a.	DISTRIBUTION/AVAILABILITY STA	TEMENT		12b. DISTRIBUTION C	ODE		
	Approved for Public release	e; distribution unlimited					
	• •						
13.	ABSTRACT (Maximum 200 words)						
13.		are commonly treated with c	utotovic age	ents (e.g. chemothe	rany radiation) that target		
	the unregulated growth east	ociated with tumors. However	yluluxic ago r many of ti	hese procedures has	ze proven unsuccessful		
	due in part to the acquired	resistance of cancer cells to the	hese regime	ns. Mounting evide	nce suggests that one		
	underlying mechanism by v	which malignancies are protect	eted from cy	totoxic agents is the	rough aberrant activation		
	of a pathway generally refe	rred to as the "stress response	e". Using a s	genetic approach in	yeast, we have identified		
	a new C-type cyclin (UME)	3) that, when deleted, allows	the inapprop	oriate expression of	the HSP70 family member		
	a new C-type cyclin (UME3) that, when deleted, allows the inappropriate expression of the HSP70 family member SSA1. Several pieces of data suggest that the human cyclin C (cycC), which exhibits nearly 40% identity to the						
	yeast gene, may also be involved in regulating the stress response. First cycC co-localizes with the human RNA						
	polymerase suggesting a ro	le for this cyclin in transcript	ional regula	tion. Second, when	expressed in yeast, cycC		
	is rapidly destroyed in cultu	ires exposed to elevated temp	eratures. Fi	nally, we have map	ped cycC to a region of the		
	genome (6q21) that is frequently deleted in breast tumors. This proposal will explore the relationship between cycC						
	activity, the stress response	and drug sensitivity.					
14.	SUBJECT TERMS			15. NUMBER OF PAGES			
1	Cyclin/stress response/drug resistance				10		
, , , , , , , , , , , , , , , , , , , ,					16. PRICE CODE		
		Breast Cancer					
17.	SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURIT OF ABST	Y CLASSIFICATION RACT	20. LIMITATION OF ABSTRACT		
	Unclassified	Unclassified	Unclas	sified	Unlimited		

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.						
() Where copyrighted material is quoted, permission has been obtained to use such material.						
() Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.						
() Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.						
() In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).						
For the protection of human subjects, the investigator(s) have adhered to policies of applicable Federal Law 32 CFR 219 and 45 CFR 46.						
(χ) In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Insitutes of Health.						
Randy Stuch Principal Investigator's Signature 8/25/99 Date						

Table of Contents

Front Cover	1
Standard Form 298	2
Foreword	3
Table of Contents	4
Introduction	5
Body	5
Conclusions	9
References	10

(5) Introduction.


Disseminated malignancies are commonly treated with cytotoxic agents (e. g., chemotherapy, radiation) which target the unregulated growth associated with tumors. However, many of these procedures have proven unsuccessful due in part to the acquired resistance of cancer cells to these regimens. Mounting evidence suggests that one underlying mechanism by which malignancies are protected from cytotoxic agents is through aberrant activation of a pathway generally referred to as the "stress response". This system, which is found in all organisms from procaryotes to man, elicits the expression of several conserved gene families (heat shock proteins e. g., Hsp70, Hsp27) that protect the cell from cytotoxic agents. In human breast cancer, overexpression of Hsp's has been associated with tumors that are both more invasive and/or resistant to chemotheraputic drugs. We propose to expand studies initiated in the budding yeast *S. cerevisiae* to investigate the role of the human cyclin C in regulating stress response genes in breast cancer tissues.

(6) Body

Object 1: Is cycC down regulated as part of the normal cellular response to stress?


Task 1: Establish human cell lines stably expressing cycC.

Stable cycC transfectants were established in two separate cell lines, Hela and MCF7 breast cancer cells. The Hela cell line was chosen to distinguish between general effects on cycC regulation from those specific for breast cancer cells. First, the cycC cDNA was obtained from Dr. S. Reed, Scripts Institute (1). The cDNA was tagged with the HA epitope (2) using standard techniques. The tagged version of cycC was inserted into the vector pCDNA3 to form pKC414 (Fig. 1) under the control of the CMV promoter which provides high, constitutive expression in many cell types.




The pKC414 plasmid was stably integrated into both Hela and MCF7 cell lines by lipofection. Transfectants were selected for neomycin resistance and subclones isolated. The clones (minimum of 10) were pooled and expanded for the experiments described below. To determine the expression levels of cycC, Western blots were performed on the cell lines using standard protein extract preparations. A band corresponding to cycC was observed in the pKC414 transfected cell lines but not in the mock transfected control (Fig. 2). These

results indicate that cycC-HA has been successfully integrated into these cell lines.



<u>Task 2: Examine cycC regulation in response to stress agents, heat shock, nutrient deprivation and hypoxia.</u>

Before cycC levels were determined in these cell lines in response to stress, the ability to evoke the stress response was determined. Antibodies directed toward the inducible form of Hsp70 were obtained from StressGen Inc. Both the Hela and MCF7 cell lines harboring the integrated cycC construct were expanded and split 48 hrs prior to testing to insure the cells were in exponential growth phase (data not shown). The cells were harvested and either protein extracts were prepared immediately, or and at various times following transfer to a 42°C water bath. Since the stress response is normally transient in nature, a timecourse was required to insure that the effects of excessive heat were not missed. Samples were taken prior to heat shock (0 hr) and at 2, 4, 6, and 8 hrs later. These times were successfully used in prior studies (3, 4). As expected, Hsp70 levels were low prior to heat shock (0 hr) but increased dramatically following exposure to elevated temperatures (Fig. 3). Due to a lack of starting material at the time of the experiment, the MCF7 sample did not have a 6 hr timepoint. Quantitation of these results indicated that Hsp70 was induced approximately 70-fold in these experiments (data not shown). Interestingly, unlike the Hela cells, the Hsp70 levels did not return to pre-heat shock levels in the MCF7 culture. Currently, it is not clear whether this represents a failure of this cell line to correctly respond to heat shock or normal experimental variation.



Our working model predicts that cycC represses Hsp70 expression. Moreover, this repression is relieved by destroying the cyclin in response to stress. Therefore, we examined cycC levels during the early timepoints of Hsp70 induction. Western blots were performed with extracts representing 0, 1 and 2 hrs following exposure of cells to elevated temperatures. These studies indicated that cycC levels were not significantly affected in either Hela or MCF7 cells (Fig. 4). Similarly, no difference in cycC levels were observed in cells exposed to stress inducing levels of ethanol or hydrogen peroxide (data not shown). These results suggest that unlike the yeast C-type cyclin, human cycC levels are not affected by stress or that the conditions used in this study were not correct to detect any changes in cycC levels.




Figure 4. cycC levels in response to heat shock. The cell lines indicated containing cycC-HA were subjected to heat shock (42°C) for the times indicated (hrs). Protein extracts were prepared and subjected to Western blot analysis with the HA monoclonal antibody. Control sample contains extract prepared from the parental MCF7 cell line lacking cycC-HA. cycC-HA specific signal is indicated by the arrow.

One significant difference in the experimental protocols used to examine the stress response in yeast and mammalian cells is the use of a recovery time following treatment in the latter system. The rationale behind recovery time is not clear but involves returning the cells to pre-stress conditions and is standardly used as the induction of many stress response genes does not occur until this period. Therefore, cycC levels were examined under conditions that used a recovery period with media containing FBS. The results of these experiments are depicted in Fig. 5. MCF7 cells were harvested, split and protein extracts were prepared immediately for the pre-heat shock control containing one half of the culture (0 hr). The remainder of the cells were subjected to heat shock (42°C) for 2 hr then allowed to recover in medium + FBS for 4.7 hr. Western blots probing for cycC of two dilutions of the extracts revealed that cycC levels were significantly reduced compared to the untreated control. These results indicate that cycC is down regulated in response to heat shock but only during the recovery period.





Figure 5. cycC levels following heat shock recovery. MCF7 stably transfected with cycC-HA were untreated (–) or heat shocked for 2 hrs followed by 4.7 hr recovery at 37°C. Extracts were prepared and the indicated amount of protein was subjected to Western blot analysis.


<u>Task 3: Examine cycC regulation in response to cytotoxic agents doxorubicin,</u> taxol, and 5-fluoro-uracil.

Due to the wide range of response kinetics observed for different stressors, an alternative approach was utilized to rapidly determine if cycC levels were affected by stress. This approach utilized tumor necrosis factor alpha or TNF α . TNF α stimulates the Jun activated kinase (JNK) cascade which triggers a general stress response. To examine whether TNF α treatment affected cycC levels, the following experiments were performed. MCF7 cells transfected with cycC-HA were treated with TNF α (2 µg/ml) for 48 hrs. Control flasks were maintained for the same period but TNF α was omitted. The results of these experiments suggest that cycC is down regulated following exposure to TNF α compared to the untreated control. These findings support our previous conclusions that cycC levels are affected by the cellular stress response pathways.



Task 4. Using directed and random mutagenesis, the cis-acting sequences the mediate cycC destruction will be sought.

The results from several experiments indicate that the stabilization of Ume3p derivaitves mutated in the CBE is not due to a defect in Cdk binding. Since stress represents a new regulatory signal governing the stability of cyclins, it may not be too surprising that a novel destruction element is involved. In addition, our finding that the A110V mutation is also able to protect Ume3p from meiosis-induced destruction [Cooper, 1997 #851] places the CBE at the intersection of a previously unknown merging of the regulatory systems governing meiosis and the stress response. Once the CBE is completely defined in yeast, the corresponding residues will be altered in cycC. The effects of these mutations on cycC destruction in response to heat shock and TNFa treatement will be deteremined.



Objective 2: Does cycC activity effect drug sensitivity in transformed or non-transformed breast cell lines?

Task 5: Examine effect of overexpression of cycC on drug resistance.

Two vectors were constructed that overexpressed cycC in cos cells. These plasmids contained an SV40 origin for plasmid replication and expressed cycC from the CMV promoter described above. The transient transfectants (and vector alone controls) were treated with three drugs used in breast cancer regimens namely doxorubicin, taxol, and 5-fluoro-uracil. No difference in viability was observed in pooled transfected exposed to either of these drugs compared to the mock transfected control (data not shown). These results indicate that overexpression of cycC alone is insufficient to cause a significant change in drug sensitivity. However, since cycC activates the cyclin dependent kinase Cdk8 (8), overexpressing the cyclin alone may not be functionally relevant. Therefore, experiments are ongoing in which the cycC and Cdk8 will be simultaneously overexpressed and the drug sensitivities re-examined.

Task 6. Examine the role of cycC in HSP gene expression.

No experiments have been completed toward this task.

<u>Task 7: Examine drug resistance of tumor cells deleted for 6q21 with or without cycC expression.</u>

No experiments have been completed toward this task.

(7) KEYRESEARCH ACCOMPLISHMENTS:

- CycC levels are reduced in response to heat shock and TNFα treatment
- A new destruction element (CBE) has been identified that is required for the destruction of the yeast C-type cyclin in response to stress and differentiation cues.

(8) Reportable outcomes.

Abstracts: Stress-Induced Destruction of C-Type Cyclins in Yeast and Man (D-14). 1996. Yeast Genetics & Human Disease. Baltimore, MD

Cell Lines. Two cell lines, Hela and MCF7, have been established that express a stably integrated cycC-HA tagged construct.

(9) CONCLUSIONS:

Similar to the findings in yeast, the human cycC levels are influenced by stress. This conclusion has been shown in two ways. First, cycC levels are reduced in cells exposed to elevated temperatures. Second, treating cells to TNF α , a known activator of

the stress response pathway, also reduces cycC concentrations. The next step will require the actual half life of cycC be determined using pulse chase experiments to ascertain whether the loss in cyclin levels is due to changes in stability or in translation efficiency.

(10) REFERENCES:

- 1. D. J. Lew, V. Dulic, S. I. Reed, *Cell* **66**, 1197-1206 (1991).
- 2. I. A. Wilson, et al., Cell 37, 767-778 (1984).
- 3. D. R. Ciocca, et al., Cancer Research **52**, 3648-3654 (1992).
- 4. D. R. Ciocca, et al., *Journal of the National Cancer Institute* **85**, 570-574 (1993).
 - 5. P. D. Jeffrey, et al., *Nature* **376**, 3113-320 (1995).
 - 6. G. Andersen, et al., *EMBO J* **16**, 958-67 (1997).
- 7. K. F. Cooper, M. J. Mallory, J. S. Smith, R. Strich, *EMBO J.* **16**, 4665-4675 (1997).
- 8. P. Rickert, W. Seghezzi, F. Shanahan, H. Cho, E. Lees, *Oncogene* **12**, 2631-2640 (1996).